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Increasing evidence indicates tumor-stromal interactions play a crucial role in cancer. An in vivo esophageal squamous cell
carcinoma (ESCC) orthotopic animal model was developed with bioluminescence imaging established with a real-timemonitoring
platform for functional and signaling investigation of tumor-stromal interactions. The model was produced by injection of
luciferase-labelled ESCC cells into the intraesophageal wall of nudemice. Histological examination indicates this orthotopic model
is highly reproducible with 100% tumorigenesis among the four ESCC cell lines tested. This new model recapitulates many clinical
and pathological properties of human ESCC, including esophageal luminal stricture by squamous cell carcinoma with nodular
tumor growth, adventitia invasion, lymphovascular invasion, and perineural infiltration. It was tested using an AKT shRNA
knockdown of ESCC cell lines and the in vivo tumor suppressive effects of AKT knockdown were observed. In conclusion, this
ESCC orthotopic mouse model allows investigation of gene functions of cancer cells in a more natural tumor microenvironment
and has advantages over previous established models. It provides a versatile platform with potential application for metastasis and
therapeutic regimen testing.
1. Introduction
Esophageal cancer (EC) is a devastating cancer with a five-
year survival ranging from 15% to 25% [1, 2]. It is ranked sixth
in cancer mortality and eighth for cancer incidence world-
wide [2–4]. Esophageal cancers are classified into two main
histological subtypes, namely, esophageal squamous cell car-
cinoma (ESCC) and esophageal adenocarcinoma (EAC).
ESCC comprises over 90% of esophageal cancers worldwide
[5–8], but EAC is rapidly becoming the predominant histo-
logical type of EC in Australia, UK, US, and western Euro-
pean countries [9, 10]. The cancer shows a wide geographical
variation with the highest prevalence region, termed the
“Asian esophageal cancer belt,” including Turkey, northeast-
ern Iran, southern and eastern Africa, and certain regions
of northern and central China such as Henan and Shanxi
[2, 11, 12]. The majority of the patients are diagnosed at
advanced metastatic stages with poor clinical outcomes [1,
2, 4]. Biomarkers for prevention, early disease detection,
prognostication of poor disease outcome, and guided ther-
apeutic treatment options are necessary to improve survival
outcomes.
Cancer development is a complex multistep process [13–
15]. Accumulation of genetic alterations leads to deregulation
of the normal intracellular signaling network and interac-
tions with the extracellular matrix environment, which are
important factors associated with cancer development [13–
16]. The tumor microenvironment and its interactions with
the tumor play a crucial role in tumor growth dynamics.
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The rationale to establish an orthotopic ESCC model is to
recapitulate more closely themicroenvironment of the tumor
in its organ of origin. Establishment of orthotopic models for
cancers in different organs has been the preferred choice for
cancer studies due to the unique tumor microenvironments
provided at different organ sites. Orthotopic animal models
provide the best fidelity for recapitulation of the tumor
microenvironment, which are invaluable for cancer and drug
development studies [16–23].
In ESCC, a limited number of orthotopic models have
been established, but all have some shortcomings. The cur-
rently available models are not well suited for functional
and signaling studies of tumor-stromal interactions and
metastasis in ESCC. Three previously established EC ortho-
topic models involved (1) surgically binding small pieces of
subcutaneous tumors to a mechanically damaged esophagus,
(2) inoculating cancer cells into the esophagus with matrigel
without any visual aids to determine actual sites inoculated,
and (3) inoculating the tumor cells into the esophageal wall
through a hole in the stomach near the gastroesophageal
junction [24–26].We have an interest in the study of the func-
tional properties and signaling pathways of tumor suppressor
genes and other candidate genes involved in ESCC cancer
development. These tumor-suppressive and antimetastatic
functions are heavily influenced by tumor-stromal interac-
tions in ESCC. Thus, we developed an ESCC orthotopic
model with pathological features highly mimicking human
ESCC tumors and allowing such questions to be addressed.
ESCC is reported to occur mainly in the lower two-thirds
of the esophagus with between 58.3% and 66% occurring
at the middle esophagus and approximately 26% to 38.9%
located in the lower third of the esophagus [27, 28]. Hence,
we developed an ESCC orthotopic model using luciferase-
labeled cell lines targeting near the middle esophagus close
to the diaphragm and away from the esophageal-stomach
junction of the esophagus of the nude mouse. This model
allows reproducible tumor formation and real-time imaging
of the tumor progression. We verified the practicality of
this system by studying the changes in a molecular pathway
utilizing an AKT (protein kinase B) shRNA knockdown
approach in ESCC cell lines to knockdown AKT, which is
frequently deregulated in cancers, to confirm its functionality
in this in vivo animal model system.
2. Materials and Methods
2.1. ESCC Cell Lines. Four luciferase-labelled ESCC cell
lines, 81-T [29], KYSE30 [30], KYSE150 [30, 31], and SLMT-1
[32], were used for in vitro and in vivo studies. The cell
lines were authenticated by the AmpFℓSTR Identifier PCR
Amplification kit (Life Technologies, Carlsbad, CA, USA).
The 81-T, KYSE30, KYSE150, and SLMT-1 cells were labelled
with luciferase [33] andwere cultured as previously described
[34].
2.2. Orthotopic Model. BALB/cAnN-nu mice at four to five
weeks of age were obtained from the Laboratory Animal Unit
at the University of Hong Kong. The orthotopic inoculation
protocol was approved by the Committee on the Use of Live
Animals in Teaching and Research. Animals were housed in
the Laboratory Animal Unit facility accredited by the Associ-
ation of Assessment and Accreditation of Laboratory Animal
Care International. The environment was kept between 16∘C
and 26∘C with relative humidity between 30 and 70% under
a regular 12-hour light, 12-hour dark cycle. Before surgery,
each mouse was anesthetized by intraperitoneal injection
of ketamine/xylazine (100mg/kg and 10mg/kg). Mice were
placed ventrally on the heating pad with the small animal
surgery system (Braintree Scientific, Braintree, MA, USA).
Disinfection with iodophors followed by 70% ethanol was
applied on the intended incision area below the left side of
the rib cage and diaphragm near the stomach prior tomaking
the incision. A skin incision no larger than one cmwasmade,
followed by an aligned peritoneal dissection. Retractors were
used to keep the incisions open for better visualization.
Connective tissues between the small left liver lobe and the
esophagus were carefully separated. The stomach was gently
pulled out caudally to create adequate tension to straighten
the esophagus for injection of cells. ESCC cells in 10 𝜇L plain
medium were inoculated with a 30G 1 cc insulin syringe
into the muscularis externa under a dissecting microscope,
SMZ445 (Nikon, Tokyo, Japan). Cell suspensionswere loaded
to the syringe one by one for each mouse after the cell
suspension was mixed well andmeasured with a Pipetman to
ensure the consistency of the cell concentration and volume
delivered. Upon observing edema forming at the inoculation
site, a cotton swab was gently pressed on the inoculation
site while removing the needle. This prevents any leakage
of cells to the peritoneal cavity and is a preventive measure
against peritoneal carcinomatosis. Vicryl absorbable sutures
were used to close the peritoneumwound.Outer skin incision
was closedwith the reflexwound clips. Animals werewarmed
by a heat lamp or heating pad until fully regaining motility.
Animal welfare was monitored as assessed by body weight,
hydration status, activity status, appetite, and behavior.
2.3. Live Imaging. Live imaging was done weekly by using
the Xenogen in vivo imaging system, IVIS-100 (Perkin Elmer,
MA, USA) to monitor the orthotopic tumor growth kinetics
of the luciferase-labelled ESCC cell lines injected into the
mice and to observe for metastasis. The 3D live images were
captured by using the Xenogen IVIS Spectrum. Luciferin
substrate (Perkin Elmer) at 150mg/kg was injected into the
animals prior to bioluminescence imaging. Animals were
euthanized at the end of the study at weeks 3 to 5 to excise
the orthotopic tumors. The tumors were dissected and fixed
in formalin and embedded in paraffin. Sectioned tissues were
stained with hematoxylin and eosin for histological examina-
tion by pathologists (Kwok Wah Chan and Alfred K. Lam).
2.4. Subcutaneous NudeMouse Tumorigenicity Assay. For the
subcutaneous injection, 1 × 106 ESCC tumor cells resus-
pended in 100 𝜇L were inoculated into the flanks of the
animals, as previously described using the BALB/cAnN-nu
mice [34].
2.5. AKT Knockdown Constructs. TheAKT knockdown olig-
onucleotides were cloned into a pLKO.1 cloning vector
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Figure 1: Surgical inoculation. (a)The needle insertion point near themiddle esophagus below the diaphragm away from the esophagogastric
junction is indicated by the arrow. (b) A thin layer of tissues covering the needle can be observed on the left side indicated by the arrow after
inserting the needle into the esophageal wall. (c) The edema in the esophagus forming after successful inoculation of cancer cells is marked
by circle and arrows. (d) A stretched esophagus with a solid orthotopic tumor is observed just below the diaphragm.
(AddGene number 10878).The AKT knockdown oligonucle-
otide sequences were obtained from The RNAi Consortium/
Public TRC portal (http://www.broadinstitute.org/rnai/pub-
lic/), targeting sequence 984 (construct ID: TRCN0000288787)
and sequence 1793 (TRCN0000199454) onAKT.A scrambled
sequence (AddGene number 1864) was used as a control.
Results from the two knockdown oligos were pooled and
analyzed against that of controls.
2.6. In Vitro Real-Time Invasion Assay. The real-time cell
invasion assay was performed by using the ACEAXcelligence
RTCA systemwithCIMplate as previously described [35, 36].
2.7. Western Blot Analysis. Western blot analysis was
performed to verify efficient knockdown of AKT expression
with AKT (Cat number 9272, Cell Signaling, Beverly, MA,
USA) and p84 (Cat number GTX70220, Genetex, Irvine, CA,
USA) was used as a loading control. Cell lysate collection and
protein purification were performed as previously described
[35].
2.8. Quantitative-PCR (Q-PCR). Q-PCRwas performedwith
SYBR-green PCR core reagent kits (Applied Biosystems, CA,
USA) in a Step-One Plus machine (Applied Biosystems, CA,
USA) and the primer sequences of IL8 and VEGFA were as
previously described [37].
2.9. Statistical Analysis. Numerical data were analyzed by the
𝑡-test, whereas the categorical data were studied by either
Fisher’s exact test or Chi-square test.
3. Results
3.1. Establishment of ESCC Orthotopic Tumors Monitored by
Live Animal Imaging. An ESCC orthotopic tumor model
recapitulating multiple histopathological characteristics of
human ESCC tumors was established by inoculating ESCC
cancer cells into themuscularis externa of the esophageal wall
near the middle esophagus below the diaphragm away from
the esophagogastric junction (Figure 1(a)). Use of a dissecting
microscope ensures that the needle was inserted underneath
the thin membrane of the esophageal wall (Figure 1(b)).
When the cells are inoculated into the muscularis externa,
edema can be observed as an indication of successful inoc-
ulation (Figure 1(c)). If the cells were injected into the lumen,
edema would be absent. A representative orthotopic solid
tumor developing after inoculation with ESCC cells was
observed near the middle esophagus below the diaphragm at
the end-point of the study (Figure 1(d)).
Cell numbers ranging between 5 × 104 and 5 × 105 for 81-
T, SLMT-1, KYSE30, and KYSE150 ESCC cell lines were tested
in this orthotopicmodel (Figure 2(a)).The cell number range
utilized was determined based on previous subcutaneous
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Figure 2: Orthotopic ESCC cell line model. (a) Different cell numbers were evaluated for orthotopic tumor formation for four ESCC cell
lines. (b) Xenogen images of 105 cells for four ESCC cell lines expressing luciferase illustrate the growth of the tumor with (A) KYSE150 luc,
(B) KYSE30 luc, (C) 81-T luc, and (D) SLMT-1 luc. (c) The bioluminescence live animal images displaying coronal, sagittal, and transaxial
cross-section views of the animal and providing tumor depth and location information of a KYSE150 orthotopic tumor in 3D taken by the
Xenogen IVIS Spectrum.
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tumorigenicity assay results and adjusted after the pilot
studies. Most tested cell lines produced 100% orthotopic
tumors using the various cell numbers tested. The optimum
cell concentrations for producing orthotopic tumors with
consistent tumor sizes and survival times for mice, as well
as being 100% tumorigenic for the tested ESCC cell lines,
KYSE150 luc and SLMT-1 luc, are 1 × 105 cells and for
KYSE30 luc and 81-T luc are 2 × 105 cells, each in a volume
of 10 𝜇L. However, a trend of earlier death after injection
of higher number of cells was observed (data not shown).
When inoculated with higher cell numbers, a small number
of the animals died within two weeks, while the majority
needed to be euthanized by three weeks due to animal welfare
issues. When inoculated with lower numbers of cells, the
survival time was generally prolonged by one to two weeks
depending on the cell line. Representative live animal images
showed the high intensity of luciferin signals for each cell
line in two dimensions (Figure 2(b)). 3D images can be
obtained by using the Xenogen Spectrum, which produces
more detailed images to visualize the depth and shape of the
tumor (Figure 2(c)).
3.2. Characterization of In Vivo Orthotopic Tumors. In order
to gain insights for the extracellular matrix interaction
between ESCC tumor cells and the stromal environment
in the esophagus, the paraffin-embedded orthotopic ESCC
tumors were carefully examined microscopically and histo-
logically by pathologists (Kwok Wah Chan and Alfred K.
Lam) after sectioning and staining with hematoxylin and
eosin (H&E). Representative H&E images from histopatho-
logical examinations of the normal esophagus and ortho-
topic tumors are shown in Figure 3. Cross sections of the
normal mouse esophagus (Figure 3(a)) and the esophagus
after inoculation with KYSE150 showing luminal stricture
due to the tumor growth (Figure 3(b)) are shown. Lympho-
vascular permeation is detected. The lesions in the animals
(Figure 3(c))were similar to those observed in human clinical
samples (Figure 3(d)) and appeared as nodular growths. The
results indicate the tumor cells were consistently inoculated
in the muscularis externa of the mouse esophagus, which
is where tumor cells are usually observed in the clinical
ESCC samples. The orthotopic tumors derived from the
KYSE150 cell line, a poorly differentiated ESCC cell line, show
invasion from mucosa to adventitia and ulceration in the
lumen of the mouse esophagus (Figures 3(e) and 3(f)). Other
common characteristics in ESCC [38], including squamous
differentiation and focal keratinization are also observed in
orthotopic tumors derived from KYSE150. Representative
H&E staining of the low histological grade orthotopic tumors
derived from another ESCC cell line, SLMT-1, is shown in
Figure 3(g). A magnified view of a large tumor nest near
the lumen of the red-boxed area (Figure 3(h)) shows a less
invasive tumor edge with the nearby tissue, compared to that
derived from KYSE150 (Figure 3(f)).
3.3. Use of the ESCC Orthotopic Model for ESCC Func-
tional and Signaling Studies Using a shRNA AKT Knockdown
Approach. Demonstration of the usefulness of the current
established ESCC orthotopic model for ESCC studies was
shown by shRNA AKT knockdown of this well-known
oncogenic signaling pathway for driving cancer. Both AKT
knockdown (KD) oligonucleotides at positions 984 and
1793 showed high efficiency reduction of AKT expression
in the tested ESCC cell lines, KYSE150, SLMT-1, and 81-T
(Figure 4(a)). The in vitro real-time invasion assay provided
further functional evidence for the successful silencing effect
of the AKT KD cell lines, which showed a significantly lower
invasiveness, when compared with the scrambled control
(Figure 4(b)). QPCR data provided additional molecular
evidence for the effectiveness of the signaling cascade of AKT
silencing. Downregulation of well-studied AKT downstream
invasion-associated markers including IL8 and VEGFA [39–
41] in the AKT knockdown cell lines was detected, as
compared to the control (Figure 4(c)). Animals were inocu-
lated with orthotopic tumors of control and AKT KD cells.
The in vivo orthotopic tumor growth was monitored by
bioluminescence. The AKT KD groups (17/25, 68%) versus
the control (12/12, 100%) showed significant tumor growth
inhibition (𝑃 = 0.0357) (Figure 4(d)).
4. Discussion
We have established a highly reproducible orthotopic animal
model for surgical inoculation of ESCC cells into nude
mice. In contrast to the esophageal adenocarcinomas, which
are reported to arise from gastric cardia near the squamo-
columnar junction and esophagogastric junction in the lower
third of the esophagus [42, 43], ESCC is most commonly
observed in the lower two-thirds of the esophagus [27].
In Hong Kong approximately 66% of the squamous cell
carcinomas arise in the middle region of the esophagus [44].
In Asian populations, the majority of the esophageal cancers
are squamous cell carcinomas. Thus, this current animal
model focused on inoculating the ESCC cells directly near the
middle portion of the esophagus close to the diaphragm, away
from the squamocolumnar junction and esophageal-stomach
junction, since the esophageal-stomach junction is where the
majority of the esophageal adenocarcinomas arise [42, 43]. In
this study, inoculation of cancer cells was done surgically into
the esophagus directly with the aid of a dissectingmicroscope
to ensure precise delivery of the cells into the esophageal wall.
Utilizing an injection volume of only 10 𝜇L cells minimizes
backpressure and leakage.The ESCC cell lines utilized in this
studywere engineered and labeledwith luciferase to allowuse
of amore sensitive in vivo imaging system for detection of the
tumor growth and metastasis.
The current established model now provides a reliable
and versatile ESCC in vivo model platform with advantages
over the previously established ESCC orthotopic models
using implantation of subcutaneous ESCC tumors onto a
mechanically damaged esophagus [25], inoculation via the
oral route [26], or injection of ESCC cells into the submucosal
layer through a hole in the stomach [24]. These earlier
orthotopic models each have limitations. Surgically binding
pieces of subcutaneous tumor to the esophagus can lead
to the outgrowth of the implanted tumor cells outside the
esophagus, invasion of surrounding tissues, and possible
obstruction of the trachea and other structures in the animals.
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Figure 3: Hematoxylin- and eosin-stained (H&E) tissue images. (a) Cross section image of a naı¨ve mouse esophagus. (b) Image of a mouse
esophagus inoculated with KYSE150 showing esophageal luminal stricture due to tumor growth indicated by arrow. (c) H&E image of a
KYSE150 orthotopic tumor containing multiple tumor nodules (indicated by arrows) with lymphovascular invasion. (d) Image of multiple
tumor nodules in human ESCC, similar to what is observed in the mouse orthotopic model shown in (c). (e) Image of poorly differentiated
KYSE150 orthotopic tumor indicates invasion from mucosa to adventitia and with lymphovascular permeation in the mouse esophagus at
week 4. (f) A magnified view of the tumor invasion edge as indicated in the red-boxed area in (e) showing ulceration in lumen resulting
from tumor invasion. (g) A cross-section H&E image of a mouse esophagus inoculated with SLMT-1. Orthotopic tumor is of low histological
grade. (h) A magnified view of red-boxed area reveals large tumor nest near the lumen.
Our experience following the described nonsurgical method
of inoculation of a mixture of matrigel and cells into the
esophagus of the animal through the oral cavity resulted in
tumor growth occurring outside the esophagus and finally
developing esophageal luminal restricture from the external
tumor due to the uncertainty of the insertion site [26]. For
the surgical method, the inoculum volume of cancer cells
was critical for successful formation of orthotopic tumors.
The inner (luminal) surface of the mouse esophagus consists
of keratinized stratified squamous epithelial cells, where
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Figure 4: AKT knockdown. (a) AKT knockdown (KD) Western blots of three ESCC cell lines indicates successful AKT knockdown. (b) In
vitro real-time invasion assays show significant inhibition in all three ESCC cell lines between vector alone (VA) and AKT KD; ∗ indicates
𝑃 < 0.05. (c) Quantitative PCR data shows inhibition in AKT downstream angiogenesis markers, IL8 and VEGFA, in all three ESCC cell
lines after AKT KD. (d) Histogram of incidence take rate, which is in terms of detectable luciferin signals after defined exposure taken at
medium field in one minute, of the orthotopic assay demonstrates significant tumor growth inhibition comparing the combined AKT KD
groups (17/25, 68%) versus the control (12/12, 100%) (𝑃 = 0.0357). Control (ctr) = scrambled oligonucleotide control.
the thickness is estimated to be approximately 3–5 layers of
cells [45]. We found that leakage of tumor cells into the
lumen with different inoculum volumes ranging from 20𝜇L
to 200𝜇L and without the aid of a dissecting microscope for
guiding inoculation in such constricted space was inevitable.
The insertion site was also a critical factor affecting the
eventual tumor formed. Tumors occasionally extended from
the lower esophagus to the stomach near the needle insertion
site at the stomach, where adenocarcinomas rather than
ESCC usually arise [24]. The reported results from Furihata
et al. show very low successful rates of orthotopic tumor
formation (1/6) after most of the tumors regressed at the
endpoint, whereas all four ESCC cell lines tested in our
current model robustly and consistently showed successful
formation of orthotopic tumors with fewer cell numbers
inoculated in smaller volumes.
Notably, our previous studies indicated KYSE150 luc
requires 1 × 106 cells for subcutaneous inoculation to obtain
100% tumorigenicity in nudemice.The subcutaneous tumors
obtained were frequently ulcerated in the central portion
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of the tumor and often showed cyst-like properties as the
subcutaneous approach could only model tumor growth and
local invasion related to the ectopic anatomical context of
the skin mesenchyme [46]. On the other hand, orthotopic
tumors derived from the KYSE150 luc cell line produced solid
tumors and required only one-tenth the inoculumof cells (1×
105 cells) to achieve 100% tumorigenicity. Most importantly,
macroscopic tissue necrosis or cyst-like properties were not
observed in the orthotopic model tumors. The current ESCC
orthotopic model provides a more optimal tissue microen-
vironment, including stromal cells, lymphatic and vascular
vessels, and the innate immune system, necessary for ESCC
in situ growth.
Histopathological examinations of the orthotopic tumors
indicate invasion frommucosa to adventitia with lymphovas-
cular permeation in the mouse esophagus. Tumor cells were
observed in mucosa, submucosa, muscles, and adventitia.
Furthermore, nodular lesions observed in orthotopic tumors
highly resemble those found in human tumors. Perineural
infiltration by squamous cell carcinoma is another commonly
observed characteristic in ESCC and was also detected in
our orthotopic tumors. Presence of perineural infiltration in
squamous cell carcinoma was reported to be significantly
correlated with cancer TNM stage, lymph node metastases,
tumor grade, and depth of tumor infiltration, which can
potentially serve as a significant independent prognosis
marker for poor overall survival [36]. This orthotopic model,
thus, recapitulates various human clinical pathological fea-
tures commonly found in ESCC, including esophageal lumi-
nal stricture, lymphovascular invasion, adventitia invasion,
perineural infiltration, and nodular tumor lesions, which
strongly resemble the human ESCC tumor-stromal microen-
vironment. Compared to subcutaneous models, orthotopic
models better recapitulate metastasis with sufficient pene-
trance and reproducibility and are useful for predicting the
clinically relevant drug dosages [19, 46].
We tested different cell numbers of the KYSE150 cells
during pilot studies, but since 1× 105 cells produced consistent
tumor sizes and survival times for other cells, then the other
cell numbers were not tested for KYSE150. A range of cell
numbers are reported that all result in 100% tumorigenicity
for the four ESCC cell lines tested (81-T, SLMT-1, KYSE30,
and KYSE150). The range utilized was from 5 × 104 to 5 × 105
cells. Depending on the need of the study, investigators have
some flexibility about choice of cell numbers to utilize in their
studies.
The usefulness of this current esophageal orthotopic
model as a platform for molecular cancer studies was further
demonstrated by silencing of the AKT gene, which is known
to play a critical role in ESCC tumorigenesis by regulating
invasion, angiogenesis, and metastasis [31, 47]. The in vivo
orthotopic tumor growth, as monitored by bioluminescence,
showed a statistically significant tumor growth inhibition
afterAKTknockdown.An in vitro inhibitory effect upon real-
time invasion assay was also observed for AKT knockdown.
The current surgical orthotopic ESCC model faithfully
mimics the human clinical pathogenesis of ESCC develop-
ment. The mutational landscape of ESCC involves multi-
ple fundamental pathways including p53, PI3K/AKT, Wnt,
and Notch pathways [48, 49]. These mutations may result
in deregulation of signaling networks intracellularly and
pathway activation disrupting the normal cell-cell and cell-
matrix interaction in the tumor microenvironment that
leads to ESCC tumorigenesis and metastasis. The newly
established ESCC orthotopic tumor model described now
provides the ideal platform for ESCC basic and preclinical
research performed under conditions closely mimicking
the expected in situ tumor microenvironment and possible
examination of key features of advanced ESCC including
local invasion and metastasis. Furthermore, the current
ESCC orthotopic model will allow rapid preclinical drug
testing and translational study of the potentially druggable
alterations such as PIK3CA, EGFR amplification, and others
from over one hundred candidates recently identified by the
genomic sequencing studies carried out in ESCC [48, 49].The
orthotopic mouse models hold promise for the potential use
for testing combinatorial therapies, new therapeutic targets,
and systemic effects of treatments with high reproducibility
[50]. We expect this newly established orthotopic model to
provide a versatile and robust system for future ESCC studies
and to have therapeutic application in pharmacokinetics and
pharmacodynamics drug discovery.
5. Conclusion
This ESCC orthotopic mouse model allows investigation
of gene functions of cancer cells in a more natural tumor
microenvironment and has advantages over previously estab-
lished models. It provides a versatile platform with potential
application for metastasis and therapeutic regimen testing.
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